Driehaus Capital Management’s Ovid Therapeutics OVID Stock Holding History

Driehaus Capital Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,400,191	Closed	-$1.82M	–	462
2025 Q3	$1.82M	Hold	1,400,191	–	–	0.01%	354
2025 Q2	$462K	Hold	1,400,191	–	–	﹤0.01%	389
2025 Q1	$437K	Hold	1,400,191	–	–	﹤0.01%	369
2024 Q4	$1.31M	Hold	1,400,191	–	–	0.01%	322
2024 Q3	$1.65M	Hold	1,400,191	–	–	0.01%	303
2024 Q2	$1.08M	Buy	+1,400,191	New	+$3.9M	0.01%	304
2023 Q2	–	Sell	-1,257,337	Closed	-$3.24M	–	449
2023 Q1	$3.24M	Sell	1,257,337 -172,931	-12%	-$410K	0.05%	311
2022 Q4	$2.66M	Hold	1,430,268	–	–	0.04%	286
2022 Q3	$2.63M	Buy	1,430,268 +86,943	+6%	+$182K	0.04%	298
2022 Q2	$2.89M	Buy	1,343,325 +983,349	+273%	+$2.38M	0.05%	291
2022 Q1	$1.13M	Buy	+359,976	New	+$1.13M	0.01%	326
2018 Q4	–	Sell	-211,107	Closed	-$1.2M	–	487
2018 Q3	$1.2M	Sell	211,107 -74,192	-26%	-$562K	0.04%	333
2018 Q2	$2.23M	Buy	285,299 +1,381	+0.5%	+$11.9K	0.08%	258
2018 Q1	$2.01M	Buy	283,918 +12,221	+4%	+$98.9K	0.07%	265
2017 Q4	$2.68M	Buy	271,697 +6,800	+3%	+$62.4K	0.1%	233
2017 Q3	$2.27M	Buy	264,897 +47,056	+22%	+$392K	0.09%	239
2017 Q2	$2.29M	Buy	+217,841	New	+$2.84M	0.08%	239

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Driehaus Capital Management's OVID Position: Q4 2025 in Review

Driehaus Capital Management sold out of Ovid Therapeutics (OVID) in Q4 2025, closing a stake of 1,400,191 shares — an estimated $1.82M sold.

Driehaus Capital Management first reported a position in OVID in Q2 2017 and held it in 17 quarters. The position peaked at $3.24M in Q1 2023. 84 funds tracked by Wall St. Rank hold OVID as of Q4 2025.

Driehaus Capital Management reported no remaining Ovid Therapeutics position as of Q4 2025 after selling out during the quarter.
Driehaus Capital Management sold 1,400,191 Ovid Therapeutics shares in Q4 2025, an estimated $1.82M.
Driehaus Capital Management first reported a position in Ovid Therapeutics in Q2 2017 and held it in 17 quarters.
Driehaus Capital Management's Ovid Therapeutics position peaked at $3.24M in Q1 2023.
84 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2025.

Based on Driehaus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.